Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Interim Management Statement

15 May 2008 07:00

Embargoed Release: 07.00hrs Thursday 15 May 2008

SOPHEON PLC ("Sopheon" or the "Company") INTERIM MANAGEMENT STATEMENT

Sopheon plc, the international provider of software and services that improve the financial return from innovation and product development investments, issues its first interim management statement for the period since 1 January 2008 to the date of this announcement, in line with the requirements of the EU Transparency Directive.

As expected we had a productive first quarter this year, recording revenues 58% higher than in the first quarter of 2007, itself a relatively strong quarter by historic standards. Since the end of 2007 we have closed a total of 13 license orders and extensions, taking our total licensee base to 145. Our consultancy business continued to add new projects both in conjunction with new license orders, and through additional sales to existing customers. Our recurring revenue base has also continued to grow, amounting to over ‚£2.8 million, up from ‚£1.8 million in May last year. As in the past, our reported results in a particular period will be affected by the timing and size of individual sales; however this continues to be offset by increasing levels of repeat business from our growing client base. We are also encouraged that revenue visibility for the full year from contracted business and recurring revenue streams now stands at ‚£5 million compared to full year revenues last year of ‚£6.3 million; meanwhile we continue to work a full sales funnel with additional sales closures expected in the current quarter.

In March we launched the most significant new release of our Accolade software solution since it was introduced to the market more than six years ago. Many of the enhancements offered in this latest version of the software are based on our work with existing customers such as General Motors and Electrolux. These new capabilities position Accolade to move beyond the process manufacturing markets that we have historically targeted and into the large aerospace, defense and automobile sectors. The combination of Accolade and Vision Strategist, the product that came to us through the acquisition of Alignent Software, constitutes the first solution set in the industry to integrate strategic product planning and product development execution. Underlining this advance, AMR Research recently identified Sopheon as the most mature product portfolio management offering in the market today.

Our product advances have been matched by investment in new recruits that bring experience in the new markets we are pursuing. That said, we very much understand the global economic situation continues to remain uncertain, and we weigh each investment decision carefully. We are confident we are making the right choices, and remain positive about the outlook for the coming year.

For further information contact:

Barry Mence, Chairman Sopheon plc + 44 (0) 1483 685 735 Arif Karimjee, CFO Vikki Krause Hansard Communications + 44 (0) 207 245 1100 + 44 (0) 7515 922906 Claire Verhagen Citigate First Financial + 31 (0) 205 754 010 David Newton Seymour Pierce + 44 (0) 207 107 8000 About Sopheon

Sopheon is an international provider of software and services that help organizations improve the business impact of product innovation. Sopheon's solutions automate and govern the innovation process, enabling companies to increase revenue and profits from new products. Sopheon is listed on the AIM Market of the London Stock Exchange and on the Euronext in the Netherlands. For more information, please visit www.sopheon.com.

vendor
Date   Source Headline
30th Jan 201810:27 amRNSIssue of Equity
29th Jan 20187:00 amRNSTrading Update
4th Jan 20182:05 pmRNSSecond Price Monitoring Extn
4th Jan 20182:00 pmRNSPrice Monitoring Extension
4th Jan 20187:00 amRNSTrading Update
22nd Dec 20171:01 pmRNSHolding(s) in Company
22nd Dec 201712:37 pmRNSConversion of Loan Stock
8th Dec 20177:00 amRNSAmendment to the Terms of Convertible Loan Stock
9th Nov 20177:00 amRNSCertis Europe Partners with Sopheon
19th Oct 20177:00 amRNSSopheon Funding Award
11th Oct 201710:44 amRNSDirector/PDMR Shareholding
2nd Oct 20177:00 amRNSIssue of Equity
26th Sep 20177:00 amRNSSopheon "Leader" in Strategic Portfolio Management
5th Sep 20177:00 amRNSSopheon's Accolade Software beyond innovation
24th Aug 20177:00 amRNSHalf Yearly Report
21st Jul 201710:32 amRNSDirector Shareholdings
6th Jul 20177:00 amRNSAccolade Release 11.2
29th Jun 20177:00 amRNSNew Approach to Product Development with Accolade
13th Jun 201712:04 pmRNSDirector Shareholdings
8th Jun 201712:09 pmRNSResult of AGM
8th Jun 20177:00 amRNSAGM Statement
26th May 20174:33 pmRNSIssue of Equity
26th Apr 20173:50 pmRNSIssue of Equity
12th Apr 201712:01 pmRNSIssue of Equity
7th Apr 20171:37 pmRNSDirector Shareholdings
31st Mar 20177:00 amRNSDirector Shareholdings
31st Mar 20177:00 amRNSIssue of Equity
23rd Mar 20177:00 amRNSFinal Results
23rd Feb 20177:00 amRNSAccolade Release 11.1
16th Feb 20177:00 amRNSGrant of Options / PDMR dealing
30th Jan 20177:00 amRNSTrading Update
21st Nov 201611:50 amRNSIssue of Equity
3rd Nov 20168:00 amRNSAccolade Release 11.0
29th Sep 201612:41 pmRNSIssue of Equity
22nd Sep 20169:09 amRNSIssue of Equity
15th Sep 20163:09 pmRNSIssue of Equity
25th Aug 20167:00 amRNSHalf Yearly Report
28th Jul 20165:01 pmRNSHolding(s) in Company
26th Jul 201610:49 amRNSHolding(s) in Company
12th Jul 201610:48 amRNSHolding(s) in Company
29th Jun 20165:32 pmRNSDirector Dealing
16th Jun 20164:22 pmRNSDirector Dealing
14th Jun 20164:18 pmRNSDirector Dealing
10th Jun 20162:13 pmRNSDirector Dealing
9th Jun 201611:37 amRNSResult of AGM
9th Jun 20167:00 amRNSAGM Statement
31st May 20163:09 pmRNSIssue of Equity
5th May 20161:25 pmRNSHolding(s) in Company
4th May 20167:00 amRNSAccolade Release 10.3
3rd May 20161:27 pmRNSDirector Shareholdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.